ECM
RIGL icon

Endurant Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Endurant Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,444
Closed -$310K – 86
2016
Q3 		$310K Buy
+8,444
New +$242K 0.11% 89

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Endurant Capital Management's RIGL Position: Q4 2016 in Review

Endurant Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2016, closing a stake of 8,444 shares — an estimated $310K sold.

Endurant Capital Management first reported a position in RIGL in Q3 2016 and held it in 1 quarter. The position peaked at $310K in Q3 2016. 107 funds tracked by Wall St. Rank hold RIGL as of Q4 2016.

  • Endurant Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Endurant Capital Management sold 8,444 Rigel Pharmaceuticals shares in Q4 2016, an estimated $310K.
  • Endurant Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Endurant Capital Management's Rigel Pharmaceuticals position peaked at $310K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2016.

Based on Endurant Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.